Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bayer Aktienges ADR (BAYRY)

Bayer Aktienges ADR (BAYRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 19,294,826
  • Shares Outstanding, K 3,929,700
  • Annual Sales, $ 51,558 M
  • Annual Income, $ -3,183 M
  • EBIT $ 550 M
  • EBITDA $ 11,395 M
  • 60-Month Beta 1.03
  • Price/Sales 0.38
  • Price/Cash Flow 1.28
  • Price/Book 0.47
  • Price/Earnings ttm 3.10
  • Earnings Per Share ttm 1.59
  • Most Recent Earnings $0.07 on 11/12/24
  • Next Earnings Date 11/13/24
  • Annual Dividend & Yield 0.02 (0.45%)
  • Most Recent Dividend 0.022 on 04/29/24
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.28
  • Number of Estimates 2
  • High Estimate 0.29
  • Low Estimate 0.26
  • Prior Year 0.50
  • Growth Rate Est. (year over year) -44.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.8600 +1.03%
on 12/19/24
5.3800 -8.74%
on 12/10/24
-0.2300 (-4.47%)
since 11/20/24
3-Month
4.8600 +1.03%
on 12/19/24
8.5800 -42.77%
on 09/30/24
-3.0800 (-38.55%)
since 09/20/24
52-Week
4.8600 +1.03%
on 12/19/24
9.7900 -49.85%
on 01/09/24
-3.8900 (-44.20%)
since 12/20/23

Most Recent Stories

More News
Regeneron Down 15.5% Year to Date: How to Play the Stock?

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during...

BAYRY : 4.9100 (-0.41%)
REGN : 701.85 (-0.90%)
RHHBY : 34.5000 (+0.76%)
SNY : 47.71 (+0.44%)
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug

Cytokinetics, Incorporated CYTK announced that the late-stage COMET-HF study on pipeline candidate, omecamtiv mecarbil, has started.COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart...

BAYRY : 4.9100 (-0.41%)
CYTK : 48.87 (+4.56%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
FDA Accepts Cytokinetics' Application for Cardiovascular Drug

Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate, aficamten.Aficamten is a next-in-class cardiac myosin inhibitor....

BAYRY : 4.9100 (-0.41%)
CYTK : 48.87 (+4.56%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

BAYRY : 4.9100 (-0.41%)
JNJ : 144.47 (+0.62%)
ORIC : 8.21 (+6.76%)
PFE : 26.36 (+2.29%)
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...

BAYRY : 4.9100 (-0.41%)
AZN : 65.35 (+1.41%)
JNJ : 144.47 (+0.62%)
MRK : 98.05 (-1.48%)
ABBV : 175.58 (+2.37%)
Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales

Bayer AG BAYRY reported third-quarter 2024 core earnings of 7 cents per American Depositary Receipt (ADR), which missed the Zacks Consensus Estimate of 17 cents. The company reported earnings of 10 cents...

BAYRY : 4.9100 (-0.41%)
JNJ : 144.47 (+0.62%)
REGN : 701.85 (-0.90%)
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea...

BAYRY : 4.9100 (-0.41%)
NVS : 97.11 (+0.35%)
REGN : 701.85 (-0.90%)
SNY : 47.71 (+0.44%)
Novartis Gets CHMP Recommendation for Kisqali in Broader Population

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali (ribociclib)...

BAYRY : 4.9100 (-0.41%)
LLY : 767.76 (+1.35%)
NVS : 97.11 (+0.35%)
Bayer Seeks Approval for Elinzanetant for Vasomotor Symptoms in EU

Bayer BAYRY announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (“EMA”) for its pipeline candidate elinzanetant.The MAA is seeking approval...

BAYRY : 4.9100 (-0.41%)
LLY : 767.76 (+1.35%)
NVS : 97.11 (+0.35%)
Roche Wins FDA Nod for Breast Cancer Drug in First-Line Setting

Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer, under the brand name Itovebi.The drug is approved in combination with Pfizer’s Ibrance...

BAYRY : 4.9100 (-0.41%)
NVS : 97.11 (+0.35%)
RHHBY : 34.5000 (+0.76%)
SNY : 47.71 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses....

See More

Key Turning Points

3rd Resistance Point 5.0067
2nd Resistance Point 4.9833
1st Resistance Point 4.9467
Last Price 4.9100
1st Support Level 4.8867
2nd Support Level 4.8633
3rd Support Level 4.8267

See More

52-Week High 9.7900
Fibonacci 61.8% 7.9067
Fibonacci 50% 7.3250
Fibonacci 38.2% 6.7433
Last Price 4.9100
52-Week Low 4.8600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar